Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Lung adenosquamous carcinoma is a relatively rare pathological type in lung cancer. The incidence of gene mutation is lower than that of lung adenocarcinoma. However, the cases of pathological transformation after targeted treatment of EGFR gene mutation are more rare.
Case Introduction: A 55 year old female was diagnosed with lung cancer and underwent surgical treatment.The pathology suggested adenosquamous cell carcinoma. Genetic test was EGFR-L858R. After surgery, she was treated with gefitinib targeted therapy. After 2 years of surgery, she developed brain metastasis. surgery was performed again. The pathology suggested squamous cell carcinoma. She continued to take gefitinib targeted therapy orally. After one month later since brain metastasis, she was found to have heart cavity metastasis and surgery was performed for the third time. Besides, the pathology suggested adenosquamous cell carcinoma. Genetic test was EGFR-p E746_ A750del, T790M (-), and we replaced with the second-generation EGFR-TKI afatinib targeted therapy. Up to now, no recurrence or metastasis has been found.
Conclusion: We now report a rare case of lung adenosquamous carcinoma with pathological transformation during targeted therapy, which is intended to provide therapeutic ideas for the treatment of lung adenosquamous carcinoma in clinical practice. In addition, we reviewed previously reported tumor heterogeneity in the literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623338 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.1029679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India.
Ann Afr Med
August 2025
Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Background: Targeted therapy and immunotherapy have improved survival and quality of life in advanced lung cancer. In this study, we evaluated the frequency of programmed death ligand-1 (PDL-1) expression in lung cancer and its association with different clinical and histological subtypes.
Materials And Methods: It is a descriptive observational study, in which patients diagnosed with lung cancer were included.
Case Report: Two cases of bronchiolar adenoma/ciliated muconodular papillary tumor characterized by significant basal cell hyperplasia and squamous metaplasia.
Front Oncol
July 2025
Department of Pathology, 920th Hospital of the Joint Logistics Support Force of Chinese People's Liberation Army, Kunming, Yunnan, China.
Background: Bronchiolar adenoma/ciliated muconodular papillary tumor (BA/CMPT) is a rare benign pulmonary tumor from the bronchiolar epithelium. Histologically, it features a continuous basal cell layer and luminal cells. Its resemblance to invasive mucinous adenocarcinoma (IMA) and acinar adenocarcinoma complicates intraoperative frozen section diagnosis.
View Article and Find Full Text PDFMagnetic resonance imaging characteristics of small cell and non-small cell lung cancer brain metastases: a retrospective study.
J Med Life
June 2025
General and Dental Radiology, Faculty of Medicine, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania.
Brain metastases (BMs) from bronchopulmonary tumors are a major cause of morbidity and mortality and significantly reduce the quality of life in oncology patients. Their treatment depends on imaging features (size, number, location) and their genetic mutation subtype, small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). In patients with SCLC, prophylactic whole-brain radiotherapy (WBRT) with hippocampal sparing (HS) is recommended, whereas in patients with NSCLC, systemic targeted therapy is preferred.
View Article and Find Full Text PDFComprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma.
J Thorac Oncol
July 2025
Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address:
In 2025, lung cancer remains the leading cause of cancer-related mortality in both men and women. Although the advent of immunotherapy and targeted therapies has revolutionized the treatment of NSCLC, treatments for rare histologic types such as adenosquamous carcinoma and pulmonary carcinosarcoma remain limited owing to insufficient data on molecular profiling. As such, knowledge of the molecular characteristics of rare tumors to inform treatment modalities for targeted approaches is desperately needed.
View Article and Find Full Text PDFBackground: Recent randomized trials have shown no significant difference in survival outcomes between lobectomy and sub-lobar resection for non-small cell lung cancer (NSCLC) ≤2 cm. However, these studies predominantly included common subtypes, such as adenocarcinoma and squamous cell carcinoma, with limited data on special type NSCLC (ST-NSCLC). This study aimed to address this gap by comparing overall survival (OS) outcomes between lobectomy and sub-lobar resection in patients with ST-NSCLC ≤2 cm.
View Article and Find Full Text PDF